HomeCompareVICA vs PFE

VICA vs PFE: Dividend Comparison 2026

VICA yields 166666.67% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VICA wins by $7.944525992890705e+28M in total portfolio value
10 years
VICA
VICA
● Live price
166666.67%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7.944525992890705e+28M
Annual income
$79,351,601,962,005,455,000,000,000,000,000,000.00
Full VICA calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — VICA vs PFE

📍 VICA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVICAPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VICA + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VICA pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VICA
Annual income on $10K today (after 15% tax)
$14,166,666.67/yr
After 10yr DRIP, annual income (after tax)
$67,448,861,667,704,640,000,000,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, VICA beats the other by $67,448,861,667,704,640,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VICA + PFE for your $10,000?

VICA: 50%PFE: 50%
100% PFE50/50100% VICA
Portfolio after 10yr
$3.972262996445352e+28M
Annual income
$39,675,800,981,002,727,000,000,000,000,000,000.00/yr
Blended yield
99.88%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

VICA
No analyst data
Altman Z
-7.3
Piotroski
1/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VICA buys
0
PFE buys
0
No recent congressional trades found for VICA or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVICAPFE
Forward yield166666.67%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$7.944525992890705e+28M$49.6K
Annual income after 10y$79,351,601,962,005,455,000,000,000,000,000,000.00$26,258.71
Total dividends collected$7.943912645651793e+28M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VICA vs PFE ($10,000, DRIP)

YearVICA PortfolioVICA Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$16,677,367$16,666,666.67$9,153$693.39+$16.67MVICA
2$25,995,051,428$25,977,206,645.90$8,593$849.25+$25995.04MVICA
3$37,869,622,473,147$37,841,807,768,118.86$8,336$1,066.78+$37869622.46MVICA
4$51,562,007,868,526,340$51,521,487,372,480,070.00$8,437$1,384.80+$51562007868.52MVICA
5$65,615,852,892,511,920,000$65,560,681,544,092,600,000.00$9,013$1,875.40+$65615852892511.91MVICA
6$78,042,202,741,585,770,000,000$77,971,993,778,990,800,000,000.00$10,306$2,680.72+$78042202741585760.00MVICA
7$86,754,863,367,545,780,000,000,000$86,671,358,210,612,300,000,000,000.00$12,820$4,101.38+$86754863367545782272.00MVICA
8$90,137,108,986,090,100,000,000,000,000$90,044,281,282,286,820,000,000,000,000.00$17,673$6,826.70+$9.01371089860901e+22MVICA
9$87,530,810,188,407,730,000,000,000,000,000$87,434,363,481,792,600,000,000,000,000,000.00$27,543$12,591.86+$8.753081018840772e+25MVICA
10$79,445,259,928,907,045,000,000,000,000,000,000$79,351,601,962,005,455,000,000,000,000,000,000.00$49,560$26,258.71+$7.944525992890705e+28MVICA

VICA vs PFE: Complete Analysis 2026

VICAStock

Rafina Innovations Inc. engages in the research, development, commercialization, and marketing of medical technologies. It operates through two segments, Clinics and Technology. The company also operates prosthetics and orthotics, and diabetic foot total rehabilitation clinics in Southern Europe, the Middle East, and North Africa. In addition, it is involved in the research, development, and commercialization of medical devices, methods, and products in the fields of prosthetics, orthotics, rehabilitation, bioengineering, mobility, diabetes, diabetic foot, tissue mechanics, ultrasonics, medical signal processing and analysis, medical technology, orthopedics, and robotic surgery; and licensing of its proprietary technologies. The company was formerly known as HCi Viocare and changed its name to Rafina Innovations Inc. in July 2018. Rafina Innovations Inc. was founded in 2007 and is based in Glasgow, the United Kingdom.

Full VICA Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this VICA vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VICA vs SCHDVICA vs JEPIVICA vs OVICA vs KOVICA vs MAINVICA vs JNJVICA vs MRKVICA vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.